NewswireToday - /newswire/ -
Irvine, CA, United States, 2014/06/02 - MDxHealth SA and HistoGeneX N.V. announced that they have been awarded $1.8M (€1.3 m) from the Flemish Institute for the Promotion of Innovation by Science and Technology (IWT) - HistoGeneX.com / MDxHealth.com. NYSE Euronext: MDXH
MDxHealth SA and HistoGeneX N.V. today announced that they have been awarded $1.8 million (€1.3 m) from the Flemish Institute for the Promotion of Innovation by Science and Technology (IWT) to fund the development of companion diagnostics for cancer immunotherapy. The joint initiative, called the Immunomics project, combines comprehensive histological profiling of tumor immune responses (including quantitative assessment of the tumor microenvironment) with advanced (epi)genome-wide molecular profiling of cancer antigens to develop a new generation of companion diagnostics that are able to predict cancer prognosis and/or response to innovative immunotherapy based therapeutic interventions.
"Our current collaboration with MDxHealth has allowed us to introduce epigenetic testing technologies to our pharmaceutical and oncology clients, further expanding our molecular capabilities and menu," said Dr. Mark Kockx, CEO of HistoGeneX. "This grant enables us to offer immunocompetent profiling, which combined with MDxHealth's next-generation sequencing capabilities, provides significant value to developers of immunotherapeutics for cancer treatment."
"The collaboration with HistoGeneX has broadened our PharmacoMDx services, expanding on our biomarker discovery program at the Center of Pharmaco (epi)Genomics, a joint-venture with Ghent University. This grant enables our partnership to expand further into the emerging field of immunotherapeutics," stated Dr. Jan Groen, CEO of MDxHealth.
MDxHealth's PharmacoMDx solutions leverage Next-Generation and Deep Sequencing technologies for the discovery of effective individualized epigenetic-based diagnostic and personalized therapeutic products. The identification and validation of epigenetic biomarkers are playing an increasingly important role in the development process of new compounds and companion diagnostics.
HistoGeneX (histogenex.com) is a molecular pathology company offering a wide range of histology, pathology and molecular diagnostic services for pharmaceutical and hospital clients, including extensive biobanking capabilities, clinical trial diagnostics and research services. HistoGeneX was established in 2001 and has built an impressive track record offering contract diagnostics. As a testimony to HistoGeneX's dedication to quality, major pharmaceutical companies have worked with HistoGeneX over the past years to generate clinical testing data as part of their regulatory submission packages and files for the FDA approval and CE marking.
MDxHealth (mdxhealth.com) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, bladder and lung cancers.
Dr. Mark Kockx - HistoGeneX
T: +32 3 218 1085 - E: kockx[.]histogenex.com
Mike Sinclair (media) - Halsin Partners
UK: +44(0)20 7318 2955 / C: +44(0)79 6802 2075
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.